The biopharmaceutical company IMV (NSDQ:IMV) has recently revealed promising data related to its lead immunotherapy as a potential ovarian cancer treatment. In the Phase 2 DeCidE1 trial, the immunotherapy DPX-Survivac with intermittent low-dose cyclophosphamide showed durable anti-tumor activity in patients with recurrent, advanced ovarian cancer.
To learn more about DPX-Survivac’s potential, we reached out to IMV Chief Medical Officer Joanne Schindler. In the following interview, Schindler touches on the standard of care for treating recurrent ovarian cancer and provides an overview of the potential of the T-cell immunotherapy for treating a range of cancers.
Could you highlight some of the main challenges in treating recurrent ovarian cancer?
Schindler: In recurrent ovarian cancer, platinum-based chemotherapy is the standard of care option for patients who have responded to prior platinum therapy and for whom recurrence was not rapid (e.g., >…